The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
Open accessAbstract
The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro . It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationGROMACS: Fast, flexible, and free
Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20291 · Cited by 19,182
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030644s · Cited by 5,177
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Self-citationA crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Self-citationChan, J. F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K. K.-W., Yuan, S., & Yuen, K.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,059
Efficient estimation of free energy differences from Monte Carlo data
Bennett, C. H. (1976) · Journal of Computational Physics · doi:10.1016/0021-9991(76)90078-4 · Cited by 2,755
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,361
Self-citationLiu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,031
Immune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation
Hashimoto, T., Perlot, T., Rehman, A., Trichereau, J., Ishiguro, H., Paolino, M., Sigl, V., Hanada, T., Hanada, R., Lipinski, S., et al. (2012) · Nature · doi:10.1038/nature11228 · Cited by 1,271
Severe acute respiratory syndrome
Peiris, J. S. M., Guan, Y., & Yuen, K. Y. (2004) · Nature Medicine · doi:10.1038/nm1143 · Cited by 1,139
Sumpter, R., Loo, Y.-M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S. M., & Gale, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2689-2699.2005 · Cited by 898
SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS
Oudit, G. Y., Kassiri, Z., Jiang, C., Liu, P. P., Poutanen, S. M., Penninger, J. M., & Butany, J. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02153.x · Cited by 893
Accurate calculation of the absolute free energy of binding for drug molecules
Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2016) · Chemical Science · doi:10.1039/c5sc02678d · Cited by 347
The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice
Imai, Y., Kuba, K., & Penninger, J. M. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.040048 · Cited by 334
Yamamoto, K., Ohishi, M., Katsuya, T., Ito, N., Ikushima, M., Kaibe, M., Tatara, Y., Shiota, A., Sugano, S., Takeda, S., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000205833.89478.5b · Cited by 323
Huang, B., Chen, Z., Geng, L., Wang, J., Liang, H., Cao, Y., Chen, H., Huang, W., Su, M., Wang, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.027 · Cited by 307
Self-citationAnti‐platelet therapy: phosphodiesterase inhibitors
Gresele, P., Momi, S., & Falcinelli, E. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04034.x · Cited by 304
Oudit, G. Y., Herzenberg, A. M., Kassiri, Z., Wong, D., Reich, H., Khokha, R., Crackower, M. A., Backx, P. H., Penninger, J. M., & Scholey, J. W. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051091 · Cited by 232
cAMP and Epac in the regulation of tissue fibrosis
Insel, P. A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L., Snead, A., Lu, D., & Aroonsakool, N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01847.x · Cited by 175
The Pulmonary Renin-Angiotensin System
Marshall, R. P. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455431 · Cited by 150
Kalinowski, L., Matys, T., Chabielska, E., Buczko, W., & Maliñski, T. (2002) · Hypertension · doi:10.1161/01.hyp.0000034745.98129.ec · Cited by 133
Kline, J. A., Garrett, J. S., Sarmiento, E. J., Strachan, C. C., & Courtney, D. M. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.005753 · Cited by 126
Antiviral drugs specific for coronaviruses in preclinical development
Adedeji, A. O., & Sarafianos, S. G. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.06.002 · Cited by 89
Platelet activation in acute pulmonary embolism
Chung, T., CONNOR, D. E., Joseph, J. E., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02461.x · Cited by 86
Inhibition of Herpes Simplex Virus Reactivation by Dipyridamole
Tenser, R. B., Gaydos, A., & Hay, K. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3657-3659.2001 · Cited by 80
Li, Z., Huang, Y., Wu, Y., Chen, J., Wu, D., Zhan, C., & Luo, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01763 · Cited by 70
Self-citationClinical pharmacokinetics of dipyridamole
Bjornsson, T. D., & Mahony, C. (1983) · Thrombosis Research · doi:10.1016/0049-3848(83)90364-x · Cited by 69
Dipyridamole Reversibly Inhibits Mengovirus RNA Replication
Fata-Hartley, C. L., & Palmenberg, A. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11062-11070.2005 · Cited by 59
Szebeni, J., Wahl, S. M., Popovic, M., Wahl, L. M., Gartner, S., Fine, R. L., Skalerič, U., Friedmann, R. M., & Weinstein, J. N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3842 · Cited by 58
Sabaeva, E., Booze, C., Atar, O. D., Eisert, C., Hanley, D. F., Serebruany, V., & for the Aggrenox® Compliance Task Force (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0158 · Cited by 13
Cited by
Neutrophil extracellular traps in COVID-19
Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., Blair, C. N., Weber, A., Barnes, B. J., Egeblad, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138999 · Cited by 1,582
Goshua, G., Pine, A. B., Meizlish, M. L., Chang, C.-H., Zhang, H., Bahel, P., Baluha, A., Bar, N., Bona, R. D., Burns, A. J., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30216-7 · Cited by 1,110
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
Zuo, Y., Estes, S. K., Ali, R. A., Gandhi, A. A., Yalavarthi, S., Shi, H., Sule, G., Gockman, K., Madison, J. A., Zuo, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3876 · Cited by 660
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
Metadata
- Authors
- Liu, X., Li, Z., Liu, S., Sun, J., Chen, Z., Jiang, M., Zhang, Q., Wei, Y., Wang, X., Huang, Y.-Y., Shi, Y., Xu, Y., Xian, H., Bai, F., Ou, C., Xiong, B., Lew, A. M., Cui, J., Fang, R., Huang, H., Zhao, J., Hong, X., Zhang, Y., Zhou, F., & Luo, H.-B.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 10
- Issue
- 7
- Pages
- 1205-1215
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3016961971
- Cited by
- 274
- References
- 44
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.